Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults

Vaccine

Volumn 30, Issue 50, 2012, Pages 7315-7320

  Gogtay, Nithya ^a   Thatte, Urmila ^a   Kshirsagar, Nilima ^a   Leav, Brett ^b   Molrine, Deborah ^b   Cheslock, Peter ^b   Kapre, Subhash V ^c   Kulkarni, Prasad S ^c  

^a KEM HOSPITAL   (India)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Serum Institute of India Ltd   (India)

Author keywords

HRIG; Post exposure prophylaxis; Rabies monoclonal antibody

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G1 ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RABIVAX; RECOMBINANT HUMAN IMMUNOGLOBULIN G1 ANTI RABIES MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ARTHRALGIA; ARTICLE; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FAINTNESS; FATIGUE; FEMALE; FLUORESCENCE; HUMAN; INDIA; INJECTION SITE PAIN; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; RAPID FLUORESCENT FOCUS INHIBITION TEST; SIDE EFFECT; SUICIDE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOTHERAPY; INDIA; MALE; POST-EXPOSURE PROPHYLAXIS; RABIES; YOUNG ADULT;

EID: 84869884411     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.027     Document Type: Article

References (27)

1. Knobel D.L., Cleaveland S., Coleman P.G., Fevre E.M., Meltzer M.I., Miranda M.E., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005, 83(May (5)):360-368.
2. Sudarshan M.K., Mahendra B.J., Madhusudana S.N., Ashwoath Narayana D.H., Rahman A., Rao N.S., et al. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J Commun Dis 2006, 38(March (1)):32-39.
3. Rabies vaccines: WHO position paper - recommendations. Vaccine 2010, 28(October (44)):7140-7142.
4. Lang J., Attanath P., Quiambao B., Singhasivanon V., Chanthavanich P., Montalban C., et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop 1998, 70(July (3)):317-333.
5. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. Adverse effects of equine rabies immune gobulin. Vaccine 1989, 7(February (1)):10-11.
6. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999, 340(April (16)):1228-1233.
7. Yu M.W., Mason B.L., Guo Z.P., Tankersley D.L., Nedjar S., Mitchell F.D., et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995, 345(May (8958)):1173-1174.
8. Fang L.X., Ping F., Ping du Y., Hui B.G., Yan Y.X. Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. Vaccine 2010, 28(October (42)):6847-6851.
9. Both L., Banyard A.C., van Dolleweerd C., Horton D.L., Ma J.K., Fooks A.R. Passive immunity in the prevention of rabies. Lancet Infect Dis 2012, 12(May (5)):397-407.
10. Kamoltham T., Singhsa J., Promsaranee U., Sonthon P., Mathean P., Thinyounyong W. Elimination of human rabies in a canine endemic province in Thailand: five-year programme. Bull World Health Organ 2003, 81(5):375-381.
11. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1(September-October (5)):443-452.
12. Enssle K., Kurrle R., Kohler R., Muller H., Kanzy E.J., Hilfenhaus J., et al. A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 1991, 10(October (5)):547-556.
13. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 2006, 193(March (6)):796-801.
14. Matsumoto T., Yamada K., Noguchi K., Nakajima K., Takada K., Khawplod P., et al. Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus. Microbiol Immunol 2010, 54(November (11)):673-683.
15. Muhamuda K., Madhusudana S.N., Ravi V. Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 2007, 3(September-October (5)):192-195.
16. Muller T., Dietzschold B., Ertl H., Fooks A.R., Freuling C., Fehlner-Gardiner C., et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 2009, 3(11):e542.
17. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 2007, 25(April (15)):2800-2810.
18. Babcock G.J., Leav B.A., Sloan S.E., Singh S., Fehlner-Gardiner C., Wandeler A., et al. Fully human monoclonal antibody 17C7 neutralizes rabies virus endemic to Asia. Rabies in the Americas XIX 2008.
19. Lumlertdacha B., Self J., Hanlon C., Sloan S., Thomas W., Ambrosino D., et al. Post-exposure prophylaxis (PEP) against Thai street rabies virus and Eurasian bat Lyssaviruses with purified chick embryo vaccine, pepsin-digested ERIG, human rabies immune globulin and a human monoclonal antibody (MAB 17C7). XVII international conference on rabies in the Americas 2006.
20. Gogtay N.J., Thatte U.M., Kulkarni P.S. Frequency and causes for exclusion from randomization of healthy volunteers screened for a phase 1 study in India. Natl Med J India 2012, 25(January-February (1)):18-20.
21. Moore S.M., Ricke T.A., Davis R.D., Briggs D.J. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals 2005, 33(December (4)):269-276.
22. Wang Y., Rowley K.J., Booth B.J., Sloan S.E., Ambrosino D.M., Babcock G.J. G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res 2011, 91(August (2)):187-194.
23. Meissner H.C., Groothuis J.R., Rodriguez W.J., Welliver R.C., Hogg G., Gray P.H., et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother 1999, 43(May (5)):1183-1188.
24. Lang J., Gravenstein S., Briggs D., Miller B., Froeschle J., Dukes C., et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 1998, 26(March (1)):7-15.
25. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26(November (47)):5922-5927.
26. Quimbao B. Evaluation of the safety and neutralizing activity of CL184, a monoclonal antibody cocktail against rabies virus, in a phase II study in healthy adolescents and children. XX international conference on rabies in the Americas 2009.
27. Prescott W.A., Doloresco F., Brown J., Paladino J.A. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010, 28(4):279-293.